2024
204 Laster Interstitial Thermal Therapy for Primary and Recurrent Meningioma: A Prospective and Retrospective Multi-institutional Study
Pugazenthi S, Leidig W, Chiang V, Rodriguez A, Prabhu S, Haskell-Mendoza A, Fecci P, Placantonakis D, Abram S, Lega B, Kim A. 204 Laster Interstitial Thermal Therapy for Primary and Recurrent Meningioma: A Prospective and Retrospective Multi-institutional Study. Neurosurgery 2024, 70: 53-54. DOI: 10.1227/neu.0000000000002809_204.Peer-Reviewed Original ResearchLaser interstitial thermal therapyInterstitial thermal therapyRecurrent meningiomasTreatment optionsTreated with laser interstitial thermal therapyFollow-upResistant to standard therapyRetrospective multi-institutional studyArmamentarium of treatment optionsCentral nervous system tumorsProgression-free survivalGrade 2 meningiomasSeries of patientsPost-procedural complicationsProspective multicenter registryNervous system tumorsMulti-institutional studyThermal therapyRecurrent tumorsOverall survivalStandard therapyMulticenter registryAblation coverageMeningioma treatmentAdult patientsLaser interstitial thermal therapy for new and recurrent meningioma: a prospective and retrospective case series.
Chiang V, Pugazenthi S, Leidig W, Rodriguez A, Prabhu S, Haskell-Mendoza A, Fecci P, Placantonakis D, Abram S, Lega B, Kim A. Laser interstitial thermal therapy for new and recurrent meningioma: a prospective and retrospective case series. Journal Of Neurosurgery 2024, 141: 642-652. PMID: 38457795, DOI: 10.3171/2023.12.jns231542.Peer-Reviewed Original ResearchLaser interstitial thermal therapyInterstitial thermal therapyRecurrent meningiomasComplication rateTreatment optionsFollow-upCohort studyResistant to standard therapyBrain tumorsProgression-free survivalOutcome dataOverall survival rateRetrospective case seriesProspective multicenter registryPatients to dateThermal therapyStandard therapyMulticenter registryAblation coverageCase seriesTumor typesAdult patientsMedian lengthMeningiomasDisease progression
2020
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases
Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T, Yomo S, Aiyama H, Higuchi Y, Shuto T, Akabane A, Sato Y, Niranjan A, Faramand AM, Lunsford LD, McInerney J, Tuanquin LC, Zacharia BE, Chiang V, Singh C, Yu JB, Braunstein S, Mathieu D, Touchette CJ, Lee CC, Yang HC, Aizer AA, Cagney DN, Chan MD, Kondziolka D, Bernstein K, Silverman JS, Grills IS, Siddiqui ZA, Yuan JC, Sheehan JP, Cordeiro D, Nosaki K, Seto T, Deibert CP, Verma V, Day S, Halasz LM, Warnick RE, Trifiletti DM, Palmer JD, Attia A, Li B, Cifarelli CP, Brown PD, Vargo JA, Combs SE, Kessel KA, Rieken S, Patel S, Guckenberger M, Andratschke N, Kavanagh BD, Robin TP. Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases. JAMA Oncology 2020, 6: 1028-1037. PMID: 32496550, PMCID: PMC7273318, DOI: 10.1001/jamaoncol.2020.1271.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyProgression-free survivalSmall-cell lung cancer (SCLC) brain metastasesCell lung cancer brain metastasesCNS progression-free survivalLung cancer brain metastasesPropensity score-matched analysisMedian overall survivalCancer brain metastasesBrain metastasesOverall survivalStereotactic radiosurgeryCentral nervous system (CNS) progression-free survivalMedian CNS progression-free survivalSRS outcomesCentral nervous system progressionSmall cell lung cancerLimited brain metastasesMulticenter cohort studyDisease control statusCell lung cancerSingle-arm trialStandard of careLeptomeningeal progressionWBRT cohort
2019
MLTI-06. BEVACIZUMAB VERSUS SURGICAL INTERVENTION FOR RADIATION NECROSIS IN PREVIOUSLY IRRADIATED BRAIN METASTASES
Hong C, Sujijantarat N, Chiang V. MLTI-06. BEVACIZUMAB VERSUS SURGICAL INTERVENTION FOR RADIATION NECROSIS IN PREVIOUSLY IRRADIATED BRAIN METASTASES. Neuro-Oncology Advances 2019, 1: i15-i15. PMCID: PMC7213266, DOI: 10.1093/noajnl/vdz014.065.Peer-Reviewed Original ResearchProgression-free survivalLaser interstitial thermal ablationBrain metastasesRadiation necrosisOverall survivalSurgical managementSurgical interventionSingle-institution chart reviewTime of interventionInterstitial thermal ablationBevacizumab cohortGood KPSLower KPSBevacizumab therapySurgery cohortChart reviewMedical managementTrue efficacyBevacizumabComparative outcomesPatientsLesionsComparison groupThermal ablationInterventionSURG-06. LASER INTERSTITIAL THERMAL THERAPY COMPARED TO CRANIOTOMY FOR TREATMENT OF RADIATION NECROSIS OR RECURRENT TUMOR IN BRAIN METASTASES FAILING RADIOSURGERY
Hong C, Deng D, Sujijantarat N, Vera A, Chiang V. SURG-06. LASER INTERSTITIAL THERMAL THERAPY COMPARED TO CRANIOTOMY FOR TREATMENT OF RADIATION NECROSIS OR RECURRENT TUMOR IN BRAIN METASTASES FAILING RADIOSURGERY. Neuro-Oncology Advances 2019, 1: i31-i32. PMCID: PMC7213364, DOI: 10.1093/noajnl/vdz014.141.Peer-Reviewed Original ResearchLaser interstitial thermal therapyProgression-free survivalBrain metastasesRadiation necrosisOverall survivalStereotactic radiosurgeryRecurrent tumorsSingle-institution chart reviewPost-operative salvagePre-operative symptomsSub-group analysisViable alternative treatmentRe-growing tumorSteroid taperNeurological outcomeChart reviewSymptom reliefUnderwent craniotomyTumor lesionsAlternative treatmentCraniotomyLocal controlPatientsMetastasisSmall lesionsLaser-interstitial thermal therapy compared to craniotomy for treatment of radiation necrosis or recurrent tumor in brain metastases failing radiosurgery
Hong CS, Deng D, Vera A, Chiang VL. Laser-interstitial thermal therapy compared to craniotomy for treatment of radiation necrosis or recurrent tumor in brain metastases failing radiosurgery. Journal Of Neuro-Oncology 2019, 142: 309-317. PMID: 30656529, DOI: 10.1007/s11060-019-03097-z.Peer-Reviewed Original ResearchConceptsLaser interstitial thermal therapyProgression-free survivalBrain metastasesRadiation necrosisOverall survivalStereotactic radiosurgeryRecurrent tumorsSingle-institution chart reviewPost-operative salvageResultsOf 75 patientsPre-operative symptomsViable alternative treatmentRe-growing tumorSteroid taperNeurological outcomeChart reviewSymptom reliefUnderwent craniotomySubgroup analysisTumor lesionsAlternative treatmentCraniotomyLocal controlMetastasisPatients
2018
Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients.
Mohammadi AM, Sharma M, Beaumont TL, Juarez KO, Kemeny H, Dechant C, Seas A, Sarmey N, Lee BS, Jia X, Fecci PE, Baehring J, Moliterno J, Chiang VL, Ahluwalia MS, Kim AH, Barnett GH, Leuthardt EC. Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients. Neurosurgery 2018, 85: 762-772. PMID: 30476325, PMCID: PMC7054708, DOI: 10.1093/neuros/nyy449.Peer-Reviewed Original ResearchConceptsProgression-free survivalDisease-specific deathOverall survivalChemo/radiotherapyPrognostic groupsOnly cohortNGBM patientsSpecific deathTumor volumeBiopsy-only patientsMedian tumor volumeFavorable prognostic factorRadiation/chemotherapyEffective treatment modalityStereotactic laser ablationMagnetic resonance imagingLA cohortMatched CohortMulticenter reviewPrognostic factorsUpfront treatmentIndependent predictorsSurvival outcomesTreatment modalitiesTumor locationSURG-20. LASER-INTERSTITIAL THERMAL THERAPY VERSUS CRANIOTOMY FOR TREATMENT OF RADIATION NECROSIS OR RECURRENT TUMOR IN BRAIN METASTASES FAILING RADIOSURGERY
Hong C, Deng J, Vera A, Chiang V. SURG-20. LASER-INTERSTITIAL THERMAL THERAPY VERSUS CRANIOTOMY FOR TREATMENT OF RADIATION NECROSIS OR RECURRENT TUMOR IN BRAIN METASTASES FAILING RADIOSURGERY. Neuro-Oncology 2018, 20: vi254-vi255. PMCID: PMC6216306, DOI: 10.1093/neuonc/noy148.1056.Peer-Reviewed Original ResearchLaser interstitial thermal therapyProgression-free survivalRe-growing tumorRadiation necrosisBrain metastasesMelanoma patientsSingle-surgeon retrospective studyImproved progression-free survivalLocal progression-free survivalPre-operative symptomsLog-rank testSteroid dosingSteroid taperNeurological outcomeOverall survivalRecurrent tumorsUnderwent craniotomyRetrospective studySingle institutionSubgroup analysisSurgery dateSurvival advantageCraniotomyPatientsLocal controlSURG-15. UPFRONT MRI-GUIDED STEREOTACTIC LASER-ABLATION IN NEWLY DIAGNOSED GLIOBLASTOMA: A MULTICENTER REVIEW OF SURVIVAL OUTCOMES COMPARED TO A MATCHED COHORT OF BIOPSY-ONLY PATIENTS
Mohammadi A, Sharma M, Beaumont T, Juarez K, Kemeny H, Dechant C, Seas A, Sarmey N, Lee B, Jia X, Fecci P, Baehring J, Moliterno J, Chiang V, Ahluwalia M, Kim A, Barnett G, Leuthardt E. SURG-15. UPFRONT MRI-GUIDED STEREOTACTIC LASER-ABLATION IN NEWLY DIAGNOSED GLIOBLASTOMA: A MULTICENTER REVIEW OF SURVIVAL OUTCOMES COMPARED TO A MATCHED COHORT OF BIOPSY-ONLY PATIENTS. Neuro-Oncology 2018, 20: vi253-vi254. PMCID: PMC6216291, DOI: 10.1093/neuonc/noy148.1051.Peer-Reviewed Original ResearchLaser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis.
Ahluwalia M, Barnett GH, Deng D, Tatter SB, Laxton AW, Mohammadi AM, Leuthardt E, Chamoun R, Judy K, Asher A, Essig M, Dietrich J, Chiang VL. Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. Journal Of Neurosurgery 2018, 130: 804-811. PMID: 29726782, DOI: 10.3171/2017.11.jns171273.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdultAgedBrain NeoplasmsFemaleHumansKarnofsky Performance StatusLaser TherapyMagnetic Resonance ImagingMaleMiddle AgedNecrosisNeoplasm Recurrence, LocalPostoperative ComplicationsProgression-Free SurvivalProspective StudiesQuality of LifeRadiation InjuriesRadiosurgeryTreatment OutcomeConceptsProgression-free survivalQuality of lifeKarnofsky Performance ScaleMulticenter prospective studyKPS scoreRecurrent tumorsStereotactic radiosurgeryOverall survivalProspective studyRadiation necrosisNeuro-Oncology Brain Metastases criteriaLocal progression-free survivalMedian KPS scoreSteroid sparing effectMetastatic brain tumorsLength of stayPercent of subjectsDuration of survivalOverall event rateSignificant differencesMajority of casesMetastasis (TNM) criteriaOS advantageProgression patientsBrain metastases
2017
Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis
Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, Beal K, Amini A, Patil T, Kavanagh BD, Camidge DR, Braunstein SE, Boreta LC, Balasubramanian SK, Ahluwalia MS, Rana NG, Attia A, Gettinger SN, Contessa JN, Yu JB, Chiang VL. Management of Brain Metastases in Tyrosine Kinase Inhibitor–Naïve Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal Of Clinical Oncology 2017, 35: jco.2016.69.714. PMID: 28113019, DOI: 10.1200/jco.2016.69.7144.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsBrain NeoplasmsCarcinoma, Non-Small-Cell LungCombined Modality TherapyCranial IrradiationDisease-Free SurvivalErbB ReceptorsErlotinib HydrochlorideFemaleHumansLung NeoplasmsMaleMiddle AgedProtein Kinase InhibitorsRadiosurgeryRetrospective StudiesSalvage TherapySurvival RateConceptsWhole brain radiotherapyMulti-institutional analysisEGFR-mutant NSCLCBrain metastasesEGFR-TKIStereotactic radiosurgeryTyrosine kinase inhibitorsOverall survivalEpidermal growth factor receptorGrowth factor receptorIntracranial progressionLung cancerMutant non-small cell lung cancerEGFR-TKI resistance mutationNon-small cell lung cancerIntracranial progression-free survivalRetrospective multi-institutional analysisDeferral of radiotherapyEGFR-TKI useSimilar prognostic featuresUpfront EGFR-TKIProgression-free survivalFactor receptorInferior overall survivalCell lung cancer
2016
BMET-24. LASER ABLATION AFTER STEREOTACTIC RADIOSURGERY (LAASR) – RESULTS OF A MULTI-CENTERED PROSPECTIVE STUDY
Chiang V, Dietrich J, Tatter S, Mohammadi A, Leuthardt E, Chamoun R, Judy K, Barnett G, Ahluwalia M. BMET-24. LASER ABLATION AFTER STEREOTACTIC RADIOSURGERY (LAASR) – RESULTS OF A MULTI-CENTERED PROSPECTIVE STUDY. Neuro-Oncology 2016, 18: vi31-vi31. DOI: 10.1093/neuonc/now212.124.Peer-Reviewed Original ResearchKarnofsky performance statusProgression-free survivalProgressive brain metastasesOverall survivalRadiation necrosisBrain metastasesMedian Karnofsky performance statusMedian KPS scorePrimary tumor pathologyPrior stereotactic radiosurgeryStereotactic radiosurgery resultsQuality of lifeOutcomes of useRN patientsSteroid usageFree survivalHospital stayKPS scorePerformance statusRANO criteriaSecondary outcomesPrimary outcomeFACT-BrRecurrent tumorsTM patientsImpact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases
Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor–Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2016, 95: 673-679. PMID: 27034176, DOI: 10.1016/j.ijrobp.2016.01.037.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyUpfront EGFR-TKIIntracranial progression-free survivalUpfront radiation therapyProgression-free survivalBrain metastasesEGFR-TKI groupEGFR-TKIEGFR-mutant NSCLCOverall survivalRadiation therapyEpidermal Growth Factor Receptor–Mutant NonDisease-specific Graded Prognostic AssessmentUpfront EGFR tyrosine kinase inhibitorsEGFR-TKI resistance mutationSmall cell lung cancerEGFR tyrosine kinase inhibitorsEGFR-TKI useMedian overall survivalSimilar overall survivalUpfront RT groupInferior overall survivalCell lung cancerMutant lung adenocarcinomaEpidermal growth factor receptor
2015
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis. Journal Of Clinical Oncology 2015, 34: 123-129. PMID: 26438117, PMCID: PMC5070549, DOI: 10.1200/jco.2015.62.0138.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnaplastic Lymphoma KinaseAntineoplastic AgentsBrain NeoplasmsCarbazolesCarcinoma, Non-Small-Cell LungCranial IrradiationCrizotinibDisease-Free SurvivalFemaleFollow-Up StudiesGene RearrangementHumansKaplan-Meier EstimateKarnofsky Performance StatusLung NeoplasmsMaleMiddle AgedMolecular Targeted TherapyNeoplasm StagingPiperidinesPrognosisProtein Kinase InhibitorsProtein-Tyrosine KinasesPyrazolesPyridinesPyrimidinesRadiosurgeryReceptor Protein-Tyrosine KinasesRisk AssessmentRisk FactorsSmokingSulfonesConceptsIntracranial progression-free survivalBrain metastasesProgression-free survivalPrognostic factorsLung cancerMedian intracranial progression-free survivalNon-small cell lung cancerTyrosine kinase inhibitor therapyProgressive brain metastasesRefinement of prognosisKarnofsky performance scorePercent of patientsClinical prognostic factorsPopulation of patientsSingle brain metastasisCell lung cancerKinase inhibitor therapyCox proportional hazardsMulti-institutional studyMedian OSExtracranial metastasesImproved survivalInhibitor therapyInitial treatmentMultivariable analysisEvolution of multidisciplinary brain metastasis management: case study and literature review.
Colaco R, Martin P, Chiang V. Evolution of multidisciplinary brain metastasis management: case study and literature review. The Yale Journal Of Biology And Medicine 2015, 88: 157-65. PMID: 26029014, PMCID: PMC4445437.Peer-Reviewed Original ResearchConceptsBrain metastasesManagement of BMProgression-free survivalLocal tumor controlLong-term survivorsNeurocognitive side effectsBrain metastasis managementSymptom reliefTumor burdenTumor controlCancer patientsTreatment modalitiesMetastasis managementSide effectsRadiation modalitiesFunctional independenceContemporary managementPatientsLiterature reviewSurvivalModalitiesOverall qualityCoordinated approachManagementPrognosis
2014
Gamma Knife Radiosurgery for Cerebellopontine Angle Meningiomas: A Multicenter Study
Ding D, Starke RM, Kano H, Nakaji P, Barnett GH, Mathieu D, Chiang V, Omay SB, Hess J, McBride HL, Honea N, Lee JY, Rahmathulla G, Evanoff WA, Alonso-Basanta M, Lunsford LD, Sheehan JP. Gamma Knife Radiosurgery for Cerebellopontine Angle Meningiomas: A Multicenter Study. Neurosurgery 2014, 75: 398-408. PMID: 24991710, DOI: 10.1227/neu.0000000000000480.Peer-Reviewed Original ResearchConceptsGamma knife radiosurgeryCerebellopontine angle meningiomaNeurological deteriorationCPA meningiomasKnife radiosurgeryNorth American Gamma Knife ConsortiumSymptomatic adverse radiation effectsTumor progressionLower maximal dosePermanent neurological deteriorationCommon presenting symptomInitial surgical resectionMulticenter cohort studyOutcomes of patientsProgression-free survivalSignificant neurological morbidityMedian tumor volumeAdverse radiation effectsMultivariate regression analysisAdjuvant treatmentNeurological morbidityPresenting symptomCohort studyMost patientsSurgical resection